FOLLOW US ON... FEEDBACK

Home >> Industry News >> Product News >> Allergan Receives FDA Approval for LUMIGAN
Allergan Receives FDA Approval for LUMIGAN PDF Print E-mail
Submit Your News
Product News
Thursday, 02 September 2010
lumigan Allergan, Inc. recently announced the United States Food and Drug Administration (FDA) has approved LUMIGAN(R) (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN(R) 0.01% is an optimized reformulation of LUMIGAN(R) (bimatoprost ophthalmic solution) 0.03%.

LUMIGAN(R) 0.01% is a once-daily prescription eye drop that provides effective and sustained IOP lowering. In a three-month study of patients with open-angle glaucoma or ocular hypertension with an average baseline of 23.5 mm Hg, LUMIGAN(R) 0.01% lowered IOP up to 7 mm Hg from baseline, with only one-third the drug exposure of LUMIGAN(R) 0.03%.1 The most common side effects of LUMIGAN(R) 0.01% are hyperemia (red eyes), eyelash growth and ocular pruritis (itchy eyes).

LUMIGAN(R) 0.01% will be available in the fourth quarter of 2010, and is the newest addition to Allergan's comprehensive glaucoma portfolio.
 

Add comment


Security code
Refresh